VSM Wealth Advisory’s AstraZeneca AZN Stock Holding History

VSM Wealth Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-235	Closed	-$32.8K	–	445
2025 Q2	$32.8K	Buy	+235	New	+$32.9K	0.01%	258

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VSM Wealth Advisory's AZN Position: Q3 2025 in Review

VSM Wealth Advisory sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 235 shares — an estimated $32.8K sold.

VSM Wealth Advisory first reported a position in AZN in Q2 2025 and held it in 1 quarter. The position peaked at $32.8K in Q2 2025. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

VSM Wealth Advisory reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
VSM Wealth Advisory sold 235 AstraZeneca shares in Q3 2025, an estimated $32.8K.
VSM Wealth Advisory first reported a position in AstraZeneca in Q2 2025 and held it in 1 quarter.
VSM Wealth Advisory's AstraZeneca position peaked at $32.8K in Q2 2025.
1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on VSM Wealth Advisory's 13F filing for Q3 2025, filed 13 Nov 2025.